Abstract 5139
Background
The prognostic value of the inflammatory indexes (eg. neutrophil-to-lymphocyte ratio, NLR; and systemic immune-inflammation index, SII) was demonstrated among patients with epithelial ovarian cancer (EOC). This study aimed to evaluate their predictive value in terms of platinum-free interval (PFI) as regard to bevacizumab treatment received.
Methods
A total of 375 EOC patients were retrospectively analyzed, 301 treated with chemotherapy alone and 74 with bevacizumab, with the decision to include this drug in the chemotherapy regimen left to the discretion of the treating physician. The correlation between NLR (defined as the ratio of neutrophil to lymphocyte count) and SII, calculated as (platelet count × neutrophil count)/lymphocyte count, and PFI were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Cutoff values were determined using Receiver Operating Characteristic (ROC) analysis.
Results
In univariate analysis, patients with high NLR (≥3) and SII (≥730) had a significantly shorter PFI at 6 and 12 months in overall cohort. In multivariate analysis, only NLR was an independent predictive factor for PFI at 6 months (OR = 2.52, 95% CI 1.30–4.87, p = 0.006) and at 12 months (OR = 2.05, 95% CI 1.05–4.01, p = 0.036) in the overall population and in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004; HR = 2.27, 95% CI 1.10–4.70, p = 0.027, respectively). Inflammatory indexes were not predictive for PFI in the bevacizumab group (Table).Table: 1020P
PFI at 6 months | PFI at 12 months | |||||||
---|---|---|---|---|---|---|---|---|
N. pts | N. pts | OR (95% CI) | p | N. pts | N. pts | OR (95% CI) | p | |
NLR | ||||||||
<3 | 74 | 139 | 1.00 | 113 | 98 | 1.00 | ||
≥3 | 80 | 68 | 2.52 (1.30-4.87) | 0.006 | 106 | 37 | 2.05 (1.05-4.01) | 0.036 |
SII | ||||||||
<730 | 52 | 99 | 1.00 | 76 | 73 | 1.00 | ||
≥730 | 102 | 108 | 0.74 (0.36-1.53) | 0.413 | 143 | 62 | 0.91 (0.45-1.84) | 0.786 |
CT | ||||||||
NLR | ||||||||
<3 | 62 | 115 | 1.00 | 98 | 78 | 1.00 | ||
≥3 | 69 | 48 | 2.77 (1.38-5.56) | 0.004 | 89 | 24 | 2.27 (1.10-4.70) | 0.027 |
SII | ||||||||
<730 | 41 | 80 | 1.00 | 63 | 56 | 1.00 | ||
≥730 | 90 | 83 | 0.76 (0.35-1.67) | 0.498 | 124 | 46 | 0.84 (0.39-1.82) | 0.663 |
CT+B | ||||||||
NLR | ||||||||
<3 | 12 | 24 | 1.00 | 15 | 20 | 1.00 | ||
≥3 | 11 | 20 | 0.47 (0.04-5.15) | 0.538 | 17 | 13 | 0.75 (0.11-5.25) | 0.774 |
SII | ||||||||
<730 | 11 | 19 | 1.00 | 13 | 17 | 1.00 | ||
≥730 | 12 | 25 | 1.65 (0.13-20.56) | 0.696 | 19 | 16 | 1.78 (0.21-15.14) | 0.599 |
Conclusions
The NLR was an independent predictive factor for platinum-sensitivity in patients with EOC treated with chemotherapy. Its predictive role seems to be lost in patients treated with bevacizumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MITO group.
Funding
MITO group.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract